Assessment of COVID-19 progression on day 5 from symptoms onset.
COVID-19
Disease progression
Outcome
Public health
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
28 Aug 2021
28 Aug 2021
Historique:
received:
28
04
2021
accepted:
20
08
2021
entrez:
29
8
2021
pubmed:
30
8
2021
medline:
25
9
2021
Statut:
epublish
Résumé
A major limitation of current predictive prognostic models in patients with COVID-19 is the heterogeneity of population in terms of disease stage and duration. This study aims at identifying a panel of clinical and laboratory parameters that at day-5 of symptoms onset could predict disease progression in hospitalized patients with COVID-19. Prospective cohort study on hospitalized adult patients with COVID-19. Patient-level epidemiological, clinical, and laboratory data were collected at fixed time-points: day 5, 10, and 15 from symptoms onset. COVID-19 progression was defined as in-hospital death and/or transfer to ICU and/or respiratory failure (PaO A total of 235 patients with COVID-19 were prospectively included in a 3-month period. The majority of patients were male (148, 63%) and the mean age was 71 (SD 15.9). One hundred and ninety patients (81%) suffered from at least one underlying illness, most frequently cardiovascular disease (47%), neurological/psychiatric disorders (35%), and diabetes (21%). Among them 88 (37%) experienced COVID-19 progression. The proposed model showed an AUC of 0.73 (95% CI 0.66-0.81) for predicting disease progression by day-11. An easy-to-use panel of laboratory/clinical parameters computed at day-5 of symptoms onset predicts, with fair discrimination ability, COVID-19 progression. Assessment of these features at day-5 of symptoms onset could facilitate clinicians' decision making. The model can also play a role as a tool to increase homogeneity of population in clinical trials on COVID-19 treatment in hospitalized patients.
Sections du résumé
BACKGROUND
BACKGROUND
A major limitation of current predictive prognostic models in patients with COVID-19 is the heterogeneity of population in terms of disease stage and duration. This study aims at identifying a panel of clinical and laboratory parameters that at day-5 of symptoms onset could predict disease progression in hospitalized patients with COVID-19.
METHODS
METHODS
Prospective cohort study on hospitalized adult patients with COVID-19. Patient-level epidemiological, clinical, and laboratory data were collected at fixed time-points: day 5, 10, and 15 from symptoms onset. COVID-19 progression was defined as in-hospital death and/or transfer to ICU and/or respiratory failure (PaO
RESULTS
RESULTS
A total of 235 patients with COVID-19 were prospectively included in a 3-month period. The majority of patients were male (148, 63%) and the mean age was 71 (SD 15.9). One hundred and ninety patients (81%) suffered from at least one underlying illness, most frequently cardiovascular disease (47%), neurological/psychiatric disorders (35%), and diabetes (21%). Among them 88 (37%) experienced COVID-19 progression. The proposed model showed an AUC of 0.73 (95% CI 0.66-0.81) for predicting disease progression by day-11.
CONCLUSION
CONCLUSIONS
An easy-to-use panel of laboratory/clinical parameters computed at day-5 of symptoms onset predicts, with fair discrimination ability, COVID-19 progression. Assessment of these features at day-5 of symptoms onset could facilitate clinicians' decision making. The model can also play a role as a tool to increase homogeneity of population in clinical trials on COVID-19 treatment in hospitalized patients.
Identifiants
pubmed: 34454452
doi: 10.1186/s12879-021-06596-5
pii: 10.1186/s12879-021-06596-5
pmc: PMC8401365
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
883Informations de copyright
© 2021. The Author(s).
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Mayo Clin Proc. 2020 Jun;95(6):1124-1126
pubmed: 32451119
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
N Engl J Med. 2020 Apr 30;382(18):e41
pubmed: 32212516
Med Sci Monit. 2020 Sep 23;26:e927167
pubmed: 32963215
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
PLoS One. 2020 Dec 7;15(12):e0243191
pubmed: 33284825
Am J Hematol. 2020 Jun;95(6):E131-E134
pubmed: 32129508
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Infect. 2020 Aug;81(2):282-288
pubmed: 32479771
Eur J Neurol. 2021 Oct;28(10):3411-3417
pubmed: 32997370
Int J Infect Dis. 2020 Sep;98:494-500
pubmed: 32619766
EClinicalMedicine. 2020 Aug;25:100449
pubmed: 32838231
Am J Emerg Med. 2021 Jul;45:638-639
pubmed: 33246860
BMC Infect Dis. 2021 Jan 18;21(1):80
pubmed: 33461497
PLoS One. 2020 Nov 3;15(11):e0241742
pubmed: 33141836
Immunol Lett. 2020 Sep;225:31-32
pubmed: 32569607
Clin Infect Dis. 2020 Jul 28;71(15):799-806
pubmed: 32271376
Hepatol Int. 2020 Sep;14(5):711-722
pubmed: 32623633
Heart. 2021 Mar;107(5):373-380
pubmed: 33334865
EClinicalMedicine. 2020 Jul 03;24:100426
pubmed: 32766541
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896